Sotorasib

A shift from intravenous to oral administration marks the next phase of Actuate Therapeutics’ (Nasdaq: ACTU) elraglusib program, after the Chicago- and Fort Worth-based company announced US FDA clearance of an investigational new drug application for an oral tablet formulation of the GSK-3β inhibitor in advanced solid tumors. Elraglusib is a small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β), a serine/threonine kinase implicated in tumor-cell survival, chemoresistance, and immune evasion through downstream effects on NF-κB signaling and the DNA damage response. The company’s decision to pursue an oral formulation follows an analysis of pharmacokinetic and outcome data from a recently completed Phase II study in metastatic pancreatic ductal adenocarcinoma (mPDAC), in which IV elraglusib combined with gemcitabine plus nab-paclitaxel produced a statistically significant improvement in overall survival. That dataset identified a positive correlation between systemic drug exposure and clinical outcomes — a finding the company said supports the hypothesis that a higher-exposure oral formulation could improve on the efficacy seen with IV dosing. The cleared IND covers a Phase I/II study of oral elraglusib as monotherapy in patients with advanced solid tumors, with initiation planned for the second half of 2026. The Phase I portion is designed to establish the maximum tolerated dose and recommended Phase II dose, while characterizing safety and pharmacokinetics. The Phase II expansion will enroll patients across four tumor types — metastatic melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer — selected on the basis of prior efficacy signals from the IV program and machine learning–assisted target analyses. Disease context and the limits of current therapy The four indications named in the oral elraglusib development plan share a common challenge: the majority of patients eventually exhaust approved options or are ineligible for existing targeted therapies due to the absence of the required biomarker. In mPDAC, the unmet need is most acute. Median overall survival with first-line therapy — either FOLFIRINOX or the combination of nab-paclitaxel (Abraxane) and gemcitabine — remains approximately 11 to 12 months. Olaparib (Lynparza), developed by AstraZeneca, is approved as maintenance therapy but only for the roughly 5 to 7% of patients with germline BRCA1/2 mutations. Pembrolizumab (Keytruda), developed by Merck, holds a tumor-agnostic approval for MSI-H tumors, but MSI-H mPDAC accounts for fewer than 2% of cases. For the approximately 95% of mPDAC patients with KRAS-mutant, microsatellite-stable disease, no approved targeted therapy exists. In metastatic melanoma, the approved landscape is more developed, encompassing anti-PD-1 agents including nivolumab (Opdivo) and pembrolizumab, dual checkpoint blockade with relatlimab plus nivolumab (Opdualag), and BRAF/MEK inhibitor combinations for the roughly 40 to 50% of patients with BRAF V600 mutations. Despite these options, post-checkpoint inhibitor failure remains a setting with limited approved alternatives beyond lifileucel (Amtagvi), Iovance Biotherapeutics’ tumor-infiltrating lymphocyte therapy, which requires intensive lymphodepletion. NSCLC and colorectal cancer present similar patterns: a growing array of biomarker-selected targeted therapies — including KRAS G12C inhibitors sotorasib (Lumakras) from Amgen and adagrasib (Krazati) from Mirati Therapeutics, now part of Bristol Myers Squibb — that leave the majority of patients without a matched targeted option. KRAS non-G12C mutations, present in approximately 75% of KRAS-mutant NSCLC cases, have no approved targeted therapy. In colorectal cancer, KRAS-mutant disease accounts for roughly 40% of cases and similarly lacks approved targeted treatment. Scientific positioning of GSK-3β inhibition GSK-3β inhibition occupies a mechanistically distinct space from all currently approved therapies across these four indications. The kinase sits at the intersection of multiple oncogenic survival pathways, regulating NF-κB–driven transcription, Wnt/β-catenin signaling, and apoptotic thresholds. Preclinical evidence suggests that GSK-3β activity contributes to resistance to both cytotoxic chemotherapy and checkpoint immunotherapy, positioning elraglusib as a potential chemosensitizer and immune modulator rather than a direct tumor-cell cytotoxin. The Phase II mPDAC data, published in Nature Medicine, provided the first clinical evidence that this mechanism translates to a survival benefit in combination with standard chemotherapy — a meaningful evidentiary step for a target that has historically been difficult to prosecute therapeutically. The company is also conducting preclinical work evaluating elraglusib in combination with RAS inhibitors, with results expected in mid-2026. No specific RAS-directed agent has been named in connection with that program. If those data support a synergistic interaction, the combination could address adaptive resistance — a recognized limitation of approved KRAS G12C inhibitors including sotorasib and adagrasib — though that hypothesis remains preclinical at this stage. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Copyright © 2026. AllSci Corp. All rights reserved.